13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
|
Name |
WKN |
Börse |
Kurs |
Datum/Zeit |
Diff. |
Diff. % |
Geld |
Brief |
Erster |
Schluss |
|
SANOFI SA INHABER EO 2 |
920657 |
Frankfurt |
88,000 |
30.05.24 14:48:38 |
-0,090 |
-0,10% |
0,000 |
0,000 |
87,480 |
88,090 |
|
REGENERON PHARMAC.DL-,001 |
881535 |
Frankfurt |
881,200 |
30.05.24 11:23:31 |
-13,800 |
-1,54% |
0,000 |
0,000 |
882,200 |
895,000 |